Promotion of good mental health, prevention, and early intervention before/at the onset of
mental disorders improve outcomes. However, the range and peak ages at onset for mental …

Background Previous research has reported increased risk for psychosis among individuals
who use cannabis during adolescence. We conducted a systematic review and meta …

Background Cannabis use following the onset of first-episode psychosis has been linked to
both increased risk of relapse and non-adherence with antipsychotic medication. Whether …

Background Cannabis is the most used recreational drug worldwide. Its use can increase
the risk of developing psychotic disorders and exacerbate their course. However, the …

Increasing evidence indicates a relationship between cannabis use and psychosis risk.
Specific factors, such as determinants of cannabis use or the genetic profile of cannabis …

Psychosocial stressors have been suggested to precipitate psychotic episodes in patients
with pre‐existing psychosis and otherwise healthy subjects. However, such a risk has never …

Background The association between cannabis use and positive symptoms in
schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet …

Background: Lurasidone is an atypical antipsychotic approved for the acute and
maintenance treatment of schizophrenia. Recently, lurasidone was also extended FDA …

Abstract Background Natural Cannabis (NC) and Synthetic Cannabinoids (SCs) use can
increase the risk of developing psychotic disorders and exacerbate their course. Aims To …

Tobacco smoking is common in schizophrenia and is one of the main causes of premature
mortality in this disorder. Little is known about clinical correlates and treatments associated …